Redpoint Investment Management Pty Ltd boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 33,351 shares of the biopharmaceutical company’s stock after purchasing an additional 1,465 shares during the period. Redpoint Investment Management Pty Ltd’s holdings in Gilead Sciences were worth $1,943,000 at the end of the most recent reporting period.
Other large investors also recently added to or reduced their stakes in the company. Advisory Alpha LLC purchased a new stake in Gilead Sciences during the 3rd quarter worth approximately $28,000. RMR Wealth Builders acquired a new stake in Gilead Sciences during the 2nd quarter valued at approximately $30,000. Price Wealth LLC lifted its stake in Gilead Sciences by 215.3% during the 3rd quarter. Price Wealth LLC now owns 514 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 351 shares during the period. Founders Capital Management acquired a new stake in Gilead Sciences during the 4th quarter valued at approximately $52,000. Finally, Adams Wealth Management acquired a new stake in Gilead Sciences during the 3rd quarter valued at approximately $54,000. 75.20% of the stock is currently owned by institutional investors.
Several equities analysts recently issued reports on the stock. Royal Bank of Canada boosted their target price on shares of Gilead Sciences from $82.00 to $86.00 in a research note on Friday, September 18th. Wells Fargo & Company dropped their target price on shares of Gilead Sciences from $69.00 to $63.00 and set an “equal weight” rating for the company in a report on Thursday, October 29th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $86.00 target price (up previously from $84.00) on shares of Gilead Sciences in a report on Thursday, October 29th. Barclays dropped their target price on shares of Gilead Sciences from $67.00 to $62.00 in a report on Thursday, October 29th. Finally, UBS Group assumed coverage on shares of Gilead Sciences in a report on Wednesday, October 28th. They issued a “neutral” rating and a $61.00 price objective for the company. Four equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $92.87.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, October 28th. The biopharmaceutical company reported $2.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.90 by $0.21. The firm had revenue of $6.58 billion for the quarter, compared to analysts’ expectations of $6.20 billion. Gilead Sciences had a net margin of 5.48% and a return on equity of 37.77%. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 6.63 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th were issued a $0.68 dividend. The ex-dividend date was Monday, December 14th. This represents a $2.72 annualized dividend and a yield of 4.42%. Gilead Sciences’s dividend payout ratio (DPR) is 44.30%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Recommended Story: When can a hold rating present a buying opportunity?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.